Spirovant Sciences, a gene therapy company developing treatments and cures for genetic respiratory diseases including cystic fibrosis, has announced the leasing of its new, expanded headquarters and laboratories at uCity Square at 3675 Market Street.
Joseph Fetterman and Clifford Brechner of the Colliers Life Sciences team led the search on Spirovant’s behalf, navigating a tightly constrained market for lab space to produce a creative solution for the firm within the robust gene and cell therapy epicenter of Philadelphia’s University City.
“In an environment where purpose-built lab space remains quite limited, Colliers and Wexford Science + Technology found that needle in a haystack - existing office space for lab conversion that enables Spirovant’s continued growth at 3675 Market Street. Colliers is pleased to have assisted Spirovant by delivering real estate solutions that matched its needs as the company grows and evolves”, noted team leader Joseph Fetterman.
In its recent market report, Converging for Cures, Colliers noted that with more than 750,000 square feet of current market demand for R&D lab and clinical scale manufacturing in the Philadelphia region, drug development companies are finding the lack of supply challenging. While the pipeline remains strong, delivery of over 1.5 million square feet of new lab space over the next two years will provide welcome relief for seekers of purpose-built lab and manufacturing space to support ongoing research and drug development.
